Isovaleric Acidemia (IVA) Treatment Market Report 2026

The isovaleric acidemia (iva) treatment market size has grown strongly in recent years. It will grow from $0.63 billion in 2025 to $0.67 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to improved newborn screening programs, increased awareness of rare metabolic disorders, availability of dietary and supplement-based management, expansion of pediatric metabolic clinics, improved survival rates in iva patients.

The isovaleric acidemia (iva) treatment market size is expected to see strong growth in the next few years. It will grow to $0.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to advancements in rare disease therapeutics, expansion of genetic counseling services, growing focus on preventive metabolic care, increasing clinical trials for gene therapy, rising investment in orphan drug development. Major trends in the forecast period include increasing adoption of early genetic screening and diagnosis, growing use of carnitine and glycine supplementation, rising focus on personalized dietary management plans, expansion of home-based long-term iva care, increasing research into gene therapy approaches.

The rising prevalence of metabolic disorders is expected to drive the growth of the isovaleric acidemia (IVA) treatment market in the coming years. Metabolic disorders are conditions that disrupt normal metabolic processes, affecting how the body converts food into energy. Common metabolic disorders include diabetes mellitus, hypothyroidism, hyperthyroidism, phenylketonuria (PKU), galactosemia, maple syrup urine disease (MSUD), isovaleric acidemia (IVA), Gaucher disease, Fabry disease, Wilson’s disease, and various lysosomal storage disorders. The increasing prevalence of these conditions is linked to lifestyle factors such as poor diet and physical inactivity, which contribute to obesity and insulin resistance. Treatments for isovaleric acidemia help manage metabolic disorders by reducing the accumulation of toxic substances in the body, restoring normal metabolic function, and preventing complications like neurological damage. For example, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, diabetes accounted for 2 million deaths. Consequently, the growing prevalence of metabolic disorders is driving the expansion of the isovaleric acidemia (IVA) treatment market.

The growing emphasis on personalized medicine is expected to drive the growth of the isovaleric acidemia (IVA) treatment market in the coming years. Personalized medicine is a healthcare approach that customizes treatment and medical decisions based on an individual’s genetic profile, lifestyle, and environment. The rising focus on personalized medicine is fueled by advances in genomic sequencing, which enable more precise identification of genetic variations linked to disease and treatment response. In the context of isovaleric acidemia (IVA), personalized medicine allows therapeutic strategies to be tailored to each patient’s specific IVD gene variants and metabolic profile, facilitating more accurate correction of enzyme dysfunction and improved clinical outcomes. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases in 2023, a substantial increase from six approvals in 2022. Consequently, the growing focus on personalized medicine is supporting the expansion of the isovaleric acidemia (IVA) treatment market.

Major companies in the isovaleric acidemia (IVA) treatment market are concentrating on precision-medicine strategies informed by advanced structural biology, such as high-resolution cryo-EM-guided small-molecule stabilizers of isovaleryl-CoA dehydrogenase (IVD). These approaches aim to enhance residual IVD enzyme activity, reduce toxic metabolite accumulation, and provide more durable metabolic correction for patients with IVA. High-resolution cryo-EM-guided small-molecule stabilizers are precision-engineered drugs designed using detailed cryo-electron microscopy structures to bind and stabilize defective IVD enzymes, helping restore normal metabolic function in isovaleric acidemia. For example, in June 2025, a research group published the cryo-EM structure of human IVD, showing that IVD forms a tetramer with a unique U-shaped substrate-binding channel and identifying key residues, such as E411, T200, and R312, which coordinate FAD and substrate interactions. These findings clarified how disease-causing mutations disrupt FAD binding, revealed novel binding pockets potentially targetable by stabilizing molecules, and provided the foundation for the rational design of small-molecule “molecular chaperones” capable of rescuing mutant IVD function - a promising next-generation therapeutic approach in the IVA treatment market.

Major companies operating in the isovaleric acidemia (iva) treatment market are Nestlé Health Science S.A., Nutricia Advanced Medical Nutrition, Nutricia Metabolics, Vitaflo International Ltd., Abbott Nutrition, Cambrooke Therapeutics Inc., Solace Nutrition LLC, Recordati Rare Diseases Inc., Targeted Medical Pharma Inc., Mead Johnson Nutrition, Ajinomoto Co. Inc., Danone S.A., Orchard Therapeutics plc, Rocket Pharmaceuticals Inc., REGENXBIO Inc., uniQure N.V., Abeona Therapeutics Inc., Bluebird Bio Inc., Editas Medicine Inc., CRISPR Therapeutics AG.

North America was the largest region in the isovaleric acidemia (IVA) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isovaleric acidemia (iva) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the isovaleric acidemia (iva) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the isovaleric acidemia treatment market by increasing costs of imported specialty nutritional products, supplements, and investigational gene therapy materials. These effects are most notable in dietary management therapies and pharmacological supplements, particularly in regions reliant on cross-border supply such as Asia-Pacific and Latin America. Higher tariffs have increased treatment costs for hospitals and homecare settings. However, tariffs have also encouraged localized production of medical nutrition products and strengthened regional supply capabilities for rare disease treatments.

The isovaleric acidemia (iva) treatment market research report is one of a series of new reports that provides isovaleric acidemia (iva) treatment market statistics, including isovaleric acidemia (iva) treatment industry global market size, regional shares, competitors with a isovaleric acidemia (iva) treatment market share, detailed isovaleric acidemia (iva) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the isovaleric acidemia (iva) treatment industry. This isovaleric acidemia (iva) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Isovaleric acidemia (IVA) treatment refers to the medical management of a rare inherited metabolic disorder caused by a deficiency of the enzyme isovaleryl-CoA dehydrogenase, resulting in the accumulation of isovaleric acid in the body. Treatment aims to reduce the buildup of toxic substances and prevent metabolic crises.

The primary types of isovaleric acidemia (IVA) treatment include classical isovaleric acidemia, moderate isovaleric acidemia, and non-classical isovaleric acidemia. Classical isovaleric acidemia is a severe inherited metabolic disorder caused by a deficiency of isovaleryl-CoA dehydrogenase, an enzyme essential for breaking down the amino acid leucine. Treatments for IVA include dietary management, enzyme replacement therapy, gene therapy, and pharmacological interventions. These treatments are administered orally or via injection and are utilized by hospitals, clinics, and homecare settings.

The isovaleric acidemia (IVA) treatment market consists of revenues earned by entities by providing services such as newborn screening programs, monitoring, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The isovaleric acidemia (IVA) treatment market includes sales of anticatabolic agents, L-carnitine supplements, and amino acid supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.